IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men

European Journal of Endocrinology

Volumn 162, Issue 2, 2010, Pages 249-257

  Yeap, Bu B ^a,b   Chubb, S A Paul ^a,b   Ho, Ken K Y ^c   Setoh, Johnson W S ^b   McCaul, Kieran A ^d   Norman, Paul E ^e   Jamrozik, Konrad ^f   Flicker, Leon ^a,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

AGE; AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AGING; BODY MASS INDEX; COHORT STUDIES; COMORBIDITY; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; METABOLIC SYNDROME X; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 75149117431     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0852     Document Type: Article

References (41)

1. Veldhuis JD. Aging and hormones of the hypothalamo-pituitary axis: gonadotropic axis in men and somatotropic axes in men and women. Ageing Research Reviews 2008 7 189-208.
2. van der Klaauw AA, Biermasz NR, Feskens EJM, Bos MB, Smit JWA, Roelfsema F, Corssmit EPM, Pijl H, Romijn JA & Pereira AM. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. European Journal of Endocrinology 2007 156 455-462.
3. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ & Murphy LJ. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clinical Endocrinology 2004 60 442-450.
4. Colao A, Di Somma C, Spiezia S, Savastano S, Rota F, Savanelli MC & Lombardi G. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 2008 93 3416-3424.
5. Janssen JAMJL, Stolk RP, Pols HAP, Grobbee DE & Lamberts SWJ. Serum total IGF1, free IGF1, and IGFBP-1 levels in an elderly population. Relation to cardiovascular risk factors and disease. Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 277-282.
6. Colangelo LA, Liu K & Gapstur SM. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and cardiovascular disease risk factors in young black men and white men. The CARDIA male hormone study. American Journal of Epidemiology 2004 160 750-757.
7. Juul A, Scheike T, Davidsen M, Gyllenborg J & Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease. A population-based case-control study. Circulation 2002 106 939-944.
8. Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K & Jorgensen JO. Insulin-like growth factor (IGF) I, -II and IGF binding protein-3 and risk of ischemic stroke. Journal of Clinical Endocrinology and Metabolism 2005 90 5937-5941.
9. Laughlin GA, Barrett-Connor E, Criqui MH & Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF1) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. Journal of Clinical Endocrinology and Metabolism 2004 89 114-120.
10. Friedrich N, Haring R, Nauck M, Ludemann J, Rosskopf D, Spilcke-Liss E, Felix SB, Dorr M, Brabant G, Volzke H & Wallaschofski H. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. Journal of Clinical Endocrinology and Metabolism 2009 94 1732-1739.
11. Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X & Psaty BM. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. Journal of Clinical Endocrinology and Metabolism 2007 92 1319-1325.
12. Fischer F, Schulte H, Mohan S, Tataru MC, Kohler E, Assmann G & von Eckardstein A. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clinical Endocrinology 2004 61 595-602.
13. Kawachi S, Takeda N, Sasaki A, Kokubo Y, Takami K, Sarui H, Hayashi M, Yamakita N & Yasuda K. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 617-621.
14. Saydah S, Graubard B, Ballard-Barbash R & Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. American Journal of Epidemiology 2007 166 518-526.
15. Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J & Kristensen LO. IGF1 as a predictor of all cause mortality and cardiovascular disease in an elderly population. European Journal of Endocrinology 2009 160 25-31.
16. Rosen CJ. Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. Clinical Chemistry 1999 45 1384-1390.
17. Firth SM & Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews 2002 23 824-854.
18. Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Malarstig A, Brismar K, Hamsten A, Fisher RM & Hellenius M-L. IGF1/IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome. Clinical Science 2009 116 507-512.
19. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A & Gibson JM. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001 44 333-339.
20. Kaushal K, Heald AH, Siddals KW, Sandhu MS, Dunger DB, Gibson JM & Wareham NJ. The impact of abnormalities in the IGF and inflammatory systems on the metabolic syndrome. Diabetes Care 2004 27 2682-2688.
21. Leinonen ES, Salonen JT, Salonen RM, Koistinen RA, Leinonen PJ, Sarna SS & Taskinen MR. Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 2002 25 1807-1812.
22. Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z & Jamrozik K. Cohort Profile: The Health In Men Study (HIMS). International Journal of Epidemiology 2009 38 48-52.
23. Charlson ME, Pompei P, Ales KL & MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987 40 373-383.
24. Alberti KGMM, Zimmet P & Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabetic Medicine 2006 23 469-480.
25. Saydah S, Ballard-Barbash R & Potischman N. Association of metabolic syndrome with insulin-like growth factors among adults in the US. Cancer Causes & Control, 2009. DOI: 10.1007/s10522-009-9351-x.
26. Maison P, Balkau B, Souberbielle JC, Cunin P, Vol S, Macquin-Mavier I & Eschwege E. Evidence for distinct effects of GH and IGF1 in the metabolic syndrome. Diabetic Medicine 2007 24 1012-1018.
27. Tong PCY, Ho C-S, Yeung VTF, Ng MCY, So W-Y, Ozaki R, Ko GTC, Ma RCW, Poon E, Chan NN, Lam CWK & Chan JCN. Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2005 90 6418-6423.
28. Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LFS, Lombardi G & Savastano S. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. European Journal of Endocrinology 2008 159 389-397.
29. Sesti G, Sciacqua A, Cardellini M, Marini MA, Maio R, Vatrano M, Succurro E, Lauro R, Federici M & Perticone F. Plasma concentration of IGF1 is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 2005 28 132-137.
30. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB & Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002 359 1740-1745.
31. Conti E, Carrozza C, Capoluongo E, Volpe M, Crea F, Zuppi C & Andreotti F. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004 110 2260-2265.
32. Unden A-L, Elofsson S & Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population based study. Clinical Endocrinology 2005 63 94-102.
33. Harrela M, Koistinen R, Tuomilehto J, Nissinen A & Seppala M. Low serum insulin-like growth factor-binding protein-1 is associated with an unfavourable cardiovascular risk profile in elderly men. Annals of Medicine 2000 32 424-428.
34. Maddux BA, Chan A, De Filippis EA, Mandarino LJ & Goldfine ID. IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Diabetes Care 2006 29 1535-1537.
35. Kotronen A, Lewitt M, Hall K, Brismar K & Yki-Jarvinen H. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. Journal of Clinical Endocrinology and Metabolism 2008 93 4867-4872.
36. Goodman-Gruen D & Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. American Journal of Epidemiology 1997 145 970-976.
37. Brugts MP, van den Beld AW, Hofland LJ, van der Wansem K, van Koetsveld PM, Frystyk J, Lamberts SWJ & Janssen JAMJL. Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. Journal of Clinical Endocrinology and Metabolism 2008 93 2515-2522.
38. Wilson PW, D'Agostino RB, Parise H, Sullivan L & Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005 112 3066-3072.
39. Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H & Eckel RH. The metabolic syndrome. Endocrine Reviews 2008 29 777-822.
40. Kalme T, Seppala M, Qiao Q, Koistinen R, Nissinen A, Harrela M, Loukovaara M, Leinonen M, Leinonen P & Tuomilehto J. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. Journal of Clinical Endocrinology and Metabolism 2005 90 1550-1556.
41. Harrela M, Qiao Q, Koistinen R, Tuomilehto J, Nissinen A, Seppala M & Leinonen P. High serum insulin-like growth factor binding protein-1 is associated with increased cardiovascular mortality in elderly men. Hormone and Metabolic Research 2002 34 144-149.